Aug 13, 2012
By:
Stephanie Sutton
AstraZeneca has paid approximately $3.2 billion to extend its diabetes alliance with Bristol-Myers Squibb (BMS), following BMS’s recently completed acquisition of Amylin Pharmaceuticals.
|
Aug 10, 2012
By:
Stephanie Sutton
The UK is to invest £8 million ($12.5 million) in a new center that will be dedicated to stem-cell biology and medicine, with the aim of developing new therapeutic approaches to illnesses that currently have no effective treatments.
|
Aug 6, 2012
By:
Stephanie Sutton
Novartis has entered into a global collaboration with the University of Pennsylvania in the US to research, develop and commercialise targeted cancer therapies.
|
Jul 30, 2012
By:
Stephanie Sutton
A report from the European Commission shows that fake pharmaceuticals were the top articles detained by European-Union customs in 2011.
|
Jul 23, 2012
By:
Stephanie Sutton
The UK's Medicines and Healthcare products Regulatory Agency has launched a public consultation regarding a scheme that could provide patients with access to unlicensed medicines in Phase II or III clinical trials.
|
Jul 18, 2012
By:
Stephanie Sutton
GlaxoSmithKline has announced that it will acquire Human Genome Sciences (HGS) for $14.25 per share in cash, or approximately $3.6 billion on an equity basis.
|
Jun 28, 2012
By:
Stephanie Sutton
The European Medicines Agency has launched an investigation into Roche after an inspection found that thousands of potential safety reports, including 15161 deaths, connected to Roche medicines had not been evaluated to determine whether they should be reported to regulators as adverse drug reactions.
|
Jun 28, 2012
By:
Stephanie Sutton
The European Medicines Agency has published its first set of finalized guidelines concerning good pharmacovigilance practices.
|
Jun 21, 2012
By:
Stephanie Sutton
Merck Serono has revealed its final “final efficiency program†for operations in Switzerland, which includes confirmation of the closure of sites in Geneva and Coinsins and their associated job cuts.
|
|
